SAB Biotherapeutics (SABS) Total Non-Current Liabilities (2020 - 2026)

SAB Biotherapeutics' Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $15.1 million for Q1 2026.

• Quarterly Total Non-Current Liabilities fell 1.66% year-over-year to $15.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.1 million (down 1.66% YoY) and the FY2025 annual result came in at $15.7 million, up 32.47% from the prior year.
• Total Non-Current Liabilities was $15.1 million for Q1 2026 at SAB Biotherapeutics, down from $15.7 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $24.4 million in Q1 2022 and bottomed at $11.7 million in Q2 2024.
• A 5-year average of $16.1 million and a median of $15.4 million in 2025 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities jumped 466.41% — and 2023, when it sank 41.17%.
• SAB Biotherapeutics' Total Non-Current Liabilities stood at $19.5 million in 2022, then declined by 23.86% to $14.9 million in 2023, then slipped by 20.39% to $11.8 million in 2024, then surged by 32.47% to $15.7 million in 2025, then retreated by 3.67% to $15.1 million in 2026.
• Business Quant data shows SABS's Total Non-Current Liabilities at $15.1 million in Q1 2026, $15.7 million in Q4 2025, and $16.0 million in Q3 2025.